Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins

• US 7,226,587 B2
• Filed: 05/31/2002
• Issued: 06/05/2007
• Est. Priority Date: 06/01/2001
• Status: Expired due to Fees

• Current Assignee: Wyeth (Pfizer Inc.)
• Original Assignee: Wyeth (Pfizer Inc.)
• Inventors: Seeherman, Howard, Pittman, Debra, Clancy, Brian
• Primary Examiner(s): WHITEMAN, BRIAN A
• Application Number:
  US10/157,839
• Publication Number:
  US 20030170208A1
• Time in Patent Office: 1,831 Days
• Field of Search: 435/320.1, 536/23.1, 536/23.5, 424/93.2
• US Class Current: 424/93.2
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/51 Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/10343 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2800/108 episomal vectors

Abstract

Compositions and methods for systemic administration of DNA encoding bone morphogenic proteins for promotion of osteogenesis are disclosed. The compositions and methods of the invention may be utilized for fracture repair. The invention further discloses compositions and methods for systemic administration of bone morphogenetic proteins for promotion of osteogenesis. These compositions and methods may be used in bone fracture healing and repair. These composition of the invention may be further utilized in increasing bone mineral density.

Claims

1. A method for promoting osteogenesis in a patient comprising systemic administration of an effective amount of a composition comprising a replication-defective adenovirus comprising a CMV promoter, wherein the promoter is operatively linked to a DNA sequence encoding a bone morphogenetic protein (BMP), wherein the DNA sequence is contained within a replication-defective, E1 and E3 minus, type 5 (del327) recombinant adenovirus, and wherein the tropism of the adenovirus is not modified.

3. The method of claim 1 or claim 2, wherein the bone morphogenetic protein is selected from the group consisting of BMP-2, BMP-4, BMP-5, BMP-6, BMP-7, BMP-10, BMP-12, BMP-13, BMP-15, BMP-16, and MP52.

4. The method of claim 3, wherein the bone morphogenetic protein is BMP-6.

2. A method for promoting fracture repair in a patient comprising systemic administration of an effective amount of a composition comprising a replication-defective adenovirus comprising a CMV promoter, wherein the promoter is operatively linked to a DNA sequence encoding a bone morphogenetic protein (BMP), wherein the DNA sequence is contained within a replication-defective, E1 and E3 minus, type 5 (del327) recombinant adenovirus, and wherein the tropism of the adenovirus is not modified.